The use of Vaccinia Immune Globulin in the Treatment of Severe Mpox. Virus Infection in Human Immunodeficiency Virus/AIDS

Andrea K Thet; Paul J Kelly; Sabirah N Kasule; Anish K Shah; Arpan Chawala; Amber Latif; Sridhar S Chilimuri; Cosmina B Zeana

doi:10.1093/cid/ciac971

The use of Vaccinia Immune Globulin in the Treatment of Severe Mpox. Virus Infection in Human Immunodeficiency Virus/AIDS

Clin Infect Dis. 2023 May 3;76(9):1671-1673. doi: 10.1093/cid/ciac971.

Authors

Andrea K Thet¹, Paul J Kelly¹, Sabirah N Kasule¹, Anish K Shah², Arpan Chawala², Amber Latif³, Sridhar S Chilimuri⁴, Cosmina B Zeana¹

Affiliations

¹ Division of Infectious Diseases, Department of Internal Medicine, BronxCare Health System, Bronx, New York, USA.
² Internal Medicine Residency, Department of Internal Medicine, BronxCare Health System affiliated with Icahn School of Medicine at Mt Sinai, Bronx, New York, USA.
³ Department of Medicine, American University of the Caribbean School of Medicine, Cupecoy, St Marteen, USA.
⁴ Department of Internal Medicine, BronxCare Health System, Bronx, New York, USA.

PMID: 36571287
DOI: 10.1093/cid/ciac971

Abstract

We report a case of progressive, severe mpox virus (MPXV) infection in a patient with AIDS despite a standard course of tecovirimat. He significantly improved after administration of vaccinia immune globulin intravenous (VIGIV) highlighting its use as an adjunct for severe disease in immunocompromised hosts.

Keywords: HIV; immune globulin; mpox; tecovirimat; vaccinia.

Publication types

Case Reports

MeSH terms

Acquired Immunodeficiency Syndrome*
HIV
Humans
Immunoglobulins
Immunologic Factors
Male
Mpox (monkeypox)*
Vaccinia* / therapy

Substances

Immunoglobulins
Immunologic Factors